Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 16/20 | 0.44 |
| ▸ | CNR1 | P21554 | 11/20 | 0.44 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13578187 | 0.95 | CNR2 (0.47) | CNR2CNR1TAS1R3TAS1R1APP | |
| Trifluoroacetic Acid SCHEMBL4329132 | 0.92 | MAP2K3 (0.45) | CNR2CNR1TAS1R3TAS1R1 | |
| Trifluoroacetic Acid SCHEMBL4322885 | 0.88 | CNR2 (0.43) | CNR2CNR1TAS1R3TAS1R1 | |
| SCHEMBL13578140 | 0.86 | MAP2K3 (0.50) | CNR2CNR1TAS1R3TAS1R1 | |
| Trifluoroacetic Acid SCHEMBL4336816 | 0.82 | MEN1 (0.43) | CNR2CNR1 | |
| SCHEMBL13578166 | 0.81 | CNR2 (0.45) | CNR2CNR1TAS1R3TAS1R1 | |
| Trifluoroacetic Acid SCHEMBL4326422 | 0.81 | L3MBTL1 (0.42) | — | |
| Trifluoroacetic Acid SCHEMBL4339706 | 0.81 | RORC (0.42) | CNR2CNR1 | |
| Trifluoroacetic Acid SCHEMBL4331249 | 0.80 | GABRA5 (0.40) | CNR1 | |
| Trifluoroacetic Acid SCHEMBL4339713 | 0.78 | CSNK1D (0.46) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | MERCK & CO., INC. | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325936-A1 | IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES | CNR2, CNR1, TRPV1 | CNR2 1/4885CNR1 2/4885TAS1R3 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.